First Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with Merckâs KEYTRUDAÂ® (pembrolizumab) Presented at 2015 ASCO Annual Meeting and Published in the New England Journal of Medicine